- Home
- ZTEK vs OPTN Comparison
ZTEK vs OPTN Comparison
Compare ZTEK & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- OPTN
- Stock Information
- Founded
- ZTEK 2008
- OPTN 2010
- Country
- ZTEK Canada
- OPTN United States
- Employees
- ZTEK N/A
- OPTN N/A
- Industry
- ZTEK Major Chemicals
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- OPTN Health Care
- Exchange
- ZTEK Nasdaq
- OPTN Nasdaq
- Market Cap
- ZTEK 103.3M
- OPTN 92.8M
- IPO Year
- ZTEK N/A
- OPTN 2017
- Fundamental
- Price
- ZTEK $1.65
- OPTN $9.40
- Analyst Decision
- ZTEK
- OPTN Hold
- Analyst Count
- ZTEK 0
- OPTN 3
- Target Price
- ZTEK N/A
- OPTN $9.00
- AVG Volume (30 Days)
- ZTEK 77.4K
- OPTN 41.7K
- Earning Date
- ZTEK 06-26-2025
- OPTN 05-20-2025
- Dividend Yield
- ZTEK N/A
- OPTN N/A
- EPS Growth
- ZTEK N/A
- OPTN N/A
- EPS
- ZTEK N/A
- OPTN N/A
- Revenue
- ZTEK $44,936.00
- OPTN $78,226,000.00
- Revenue This Year
- ZTEK N/A
- OPTN $30.49
- Revenue Next Year
- ZTEK N/A
- OPTN $13.51
- P/E Ratio
- ZTEK N/A
- OPTN N/A
- Revenue Growth
- ZTEK 92.38
- OPTN 10.20
- 52 Week Low
- ZTEK $0.50
- OPTN $4.82
- 52 Week High
- ZTEK $1.31
- OPTN $20.03
- Technical
- Relative Strength Index (RSI)
- ZTEK 65.29
- OPTN 76.14
- Support Level
- ZTEK $1.51
- OPTN $9.14
- Resistance Level
- ZTEK $1.83
- OPTN $9.45
- Average True Range (ATR)
- ZTEK 0.18
- OPTN 0.08
- MACD
- ZTEK 0.02
- OPTN -0.07
- Stochastic Oscillator
- ZTEK 79.13
- OPTN 80.71
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.